Several ongoing trials are evaluating anti-CD38 therapy in combination regimens, including with agents that target B-cell maturation antigen; the bispecific antibodies teclistamab and talquetamab are being assessed with daratumumab for RRMM, while ciltacabtagene autoleucel, a chimeric antigen receptor T-cell treatment, is being assessed with daratumumab for newly-diagnosed MM (51–53). Here, CD38 is linked to Miyoshi myopathy.